TG Therapeutics, Inc. (TGTX) Stock Price, Chart & Analysis

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Sector

Healthcare

Industry

Biotechnology

Exchange

NCM

CEO

Mr. Michael S. Weiss Esq., J.D.

Employees

399

IPO year

2010

Market cap

$9.4B

P/E (TTM)

22.29

Forward P/E

22.64

EPS (TTM)

$2.75

Book value

$4.26

52-week range

$26.76 – $61.76

Beta

1.80

Revenue (TTM)

$799.5M

Profit margin

55.2%

Return on equity

100.3%